


II. AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A compound of the formula (I):



(I)

wherein

R_1 is selected from the group consisting of C_1 or C_{3-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_2 and R_3 are independently selected from the group consisting of ~~hydrogen~~, C_{4-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_4 is selected from the group consisting of a bond and C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen or oxo groups;

R_5 is selected from the group consisting of ~~hydrogen~~, a 5 or 6 membered aromatic or heteroaromatic group, and a C_{3-12} cycloalkyl;


R_6 is selected from the group consisting of C_{1-10} alkyl, C_{3-12} cycloalkyl; and

n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

2. **(Cancelled)**

3. **(Original)** A compound of claim 1 wherein R_2 is butyl.

4. **(Original)** A compound of claim 1 wherein R_4 is selected from a bond, methyl, or ethyl, wherein the methyl and ethyl are optionally substituted with an oxo group.
5. **(Original)** A compound of claim 1, wherein R_5 is phenyl.
6. **(Original)** A compound of claim 1 selected from 1-benzylamino-3-dibutylamino-propyl; 1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-dibutylamino-propyl; and pharmaceutically acceptable salts thereof.
7. **(Previously presented)** A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
8. - 10. **(Withdrawn)**
11. **(Currently amended)** A compound of the formula (I):



(I)

wherein

- R_1 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;
 R_2 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;
 R_3 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10}

alkenyl and C₂₋₁₀ alkenylene;

R₄ is selected from the group consisting of a bond, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl and C₂₋₁₀ alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen groups;

R₅ is selected from the group consisting of **hydrogen**, a 5 or 6 membered aromatic or heteroaromatic group, and a C₃₋₁₂ cycloalkyl;

R₆ is selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl and halogen; and
n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

12. **(Previously presented)** A compound of claim 11 wherein R₁ is propyl.

13. **(Cancelled)**


14. **(Previously presented)** A compound of claim 11 wherein R₄ is selected from a bond, methyl or ethyl, wherein the methyl and ethyl are optionally substituted with a halogen group.

15. **(Cancelled)**

16. **(Previously presented)** A pharmaceutical composition comprising a compound of claim 11 and at least one pharmaceutically acceptable excipient.

17. - 22. **(Cancelled)**

23. **(Previously presented)** A compound of the formula (I):



(I)

wherein

R_1 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_2 is selected from the group consisting of hydrogen, C_{5-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_3 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_4 is selected from the group consisting of a bond and C_{1-10} alkyl, C_{2-10} alkenyl and a C_{2-10} alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen or oxo groups;

R_5 is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a C_{3-12} cycloalkyl;

R_6 is selected from the group consisting of C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen; and n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

24. **(Previously presented)** A pharmaceutical composition comprising a compound of claim 23 and at least one pharmaceutically acceptable excipient.